These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 554446)

  • 41. Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.
    Shvartsburd A; Nwokeafor V; Smith RC
    Psychopharmacology (Berl); 1984; 82(1-2):55-61. PubMed ID: 6420831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Intravenous haloperidol (Serenase) in treatment of severe psychomotor agitation].
    Skausig OB
    Ugeskr Laeger; 1979 Dec; 141(49):3371-2. PubMed ID: 524519
    [No Abstract]   [Full Text] [Related]  

  • 43. Plasma neuroleptic and prolactin levels in mentally retarded patients.
    Linnolia M; Viukari M; Vaisanen K; Auvinen J
    Acta Pharmacol Toxicol (Copenh); 1980 Feb; 46(2):159-60. PubMed ID: 6102427
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
    Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
    Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro.
    Rowell FJ; Hui SM; Fairbairn AF; Eccleston D
    Br J Clin Pharmacol; 1981 Apr; 11(4):377-82. PubMed ID: 7259931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Haloperidol versus thioridazine for hospitalized psychogeriatric patients: double-blind study.
    Tsuang MM; Lu LM; Stotsky BA; Cole JO
    J Am Geriatr Soc; 1971 Jul; 19(7):593-600. PubMed ID: 4937658
    [No Abstract]   [Full Text] [Related]  

  • 47. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
    Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
    J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol.
    Hennessy S; Bilker WB; Knauss JS; Kimmel SE; Margolis DJ; Morrison MF; Reynolds RF; Glasser DB; Strom BL
    Br J Clin Pharmacol; 2004 Jul; 58(1):81-7. PubMed ID: 15206997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful suicides with thioridazine and mesoridazine: a result of probable cardiotoxicity.
    Donlon PT; Tupin JP
    Arch Gen Psychiatry; 1977 Aug; 34(8):955-7. PubMed ID: 889420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma and red cell levels of thioridazine and clinical response in schizophrenia.
    Smith RC; Baumgartner R; Ravichandran GK; Shvartsburd A; Schoolar JC; Allen P; Johnson R
    Psychiatry Res; 1984 Aug; 12(4):287-96. PubMed ID: 6594712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites.
    Rao ML; Brown WA; Wagner R
    Ther Drug Monit; 1988; 10(2):184-7. PubMed ID: 3381236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
    von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
    Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
    Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
    Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
    [No Abstract]   [Full Text] [Related]  

  • 54. Studies on thioridazine and mesoridazine metabolism. II. In vivo metabolism of tritiated drugs in rhesus monkeys.
    Forrest IS; Green DE; Blum A; Serra MT; Loeffler KO
    Commun Psychopharmacol; 1979; 3(5):323-7. PubMed ID: 121276
    [No Abstract]   [Full Text] [Related]  

  • 55. A pilot of plasma thioridazine and metabolites in chronically treated patients.
    Papadopoulos AS; Chand TG; Crammer JL; Lader S
    Br J Psychiatry; 1980 Jun; 136():591-6. PubMed ID: 7388266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of haloperidol to control agitation/violence during admission to an alcohol detoxification center.
    Benforado JM; Houden D
    Curr Alcohol; 1979; 7():331-8. PubMed ID: 552330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Studies on thioridazine and mesoridazine metabolism. I. Protein binding.
    Forrest IS; Green DE; Blum A; Serra MT; Loeffler KO
    Commun Psychopharmacol; 1979; 3(5):319-22. PubMed ID: 548210
    [No Abstract]   [Full Text] [Related]  

  • 58. Simultaneous assay of thioridazine and its major metabolites in plasma at single dosage levels with a novel report of two ring sulfoxides of thioridazine.
    Wells CE; Juenge EC; Furman WB
    J Pharm Sci; 1983 Jun; 72(6):622-5. PubMed ID: 6875822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Double-blind assessment of mellaril in a mentally retarded population using detailed evaluations [proceedings].
    Heistad GT; Zimmermann RL
    Psychopharmacol Bull; 1979 Apr; 15(2):86-8. PubMed ID: 373010
    [No Abstract]   [Full Text] [Related]  

  • 60. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites.
    Cohen BM; Lipinski JF; Waternaux C
    Psychopharmacology (Berl); 1989; 97(4):481-8. PubMed ID: 2498945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.